Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-08-02

AUTHORS

Michelle Stewart, Shannon Shaffer, Brian Murphy, Jane Loftus, Jose Alvir, Michael Cicchetti, William R. Lenderking

ABSTRACT

INTRODUCTION: Transthyretin amyloidosis (ATTR amyloidosis), whether manifesting as familial amyloid polyneuropathy (ATTR-PN) or cardiomyopathy (ATTR-CM), is a progressive, debilitating, and often fatal, rare disease requiring significant caregiver support. This study aims to better characterize the burden of disease for ATTR amyloidosis patients and caregivers. METHODS: Patients and caregivers in the USA and Spain were recruited through patient advocacy groups to complete a cross-sectional survey. Assessments included the 12-Item Short Form Health Survey, the Work Productivity and Activity Impairment Questionnaire, the Zarit Burden Interview, pain and symptom measures, health care resource use measures, and caregiving burden measures. RESULTS: Respondents included 60 ATTR amyloidosis patients and 32 caregivers. Patients registered scores up to two standard deviations below normal for physical health, impairment in quality of life, and reduced work productivity. Patients with liver transplant versus without liver transplant reported better overall outcomes, and those without liver transplant reported a greater impact on physical versus mental health. A high rate of health care utilization in the 3 months prior to the survey was reported by patients. Caregivers reported substantial burden, including poor mental health, work impairment, and much time spent providing care (mean 45.9 h/week). Work productivity was impacted for employed patients and caregivers. CONCLUSION: ATTR amyloidosis was associated with high levels of impairment in many domains, including physical health, quality of life, and reduced productivity. Providing care for ATTR amyloidosis patients is associated with a negative impact on the mental health of caregivers. These results highlight the substantial burden of ATTR amyloidosis for patients and caregivers. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01604122. FUNDING: Pfizer. More... »

PAGES

349-364

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40120-018-0106-z

DOI

http://dx.doi.org/10.1007/s40120-018-0106-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105964805

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30073497


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, NY USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stewart", 
        "givenName": "Michelle", 
        "id": "sg:person.010273426173.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010273426173.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evidera, Bethesda, MD USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Evidera, Bethesda, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shaffer", 
        "givenName": "Shannon", 
        "id": "sg:person.0721626343.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721626343.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evidera, Bethesda, MD USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Evidera, Bethesda, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Murphy", 
        "givenName": "Brian", 
        "id": "sg:person.0616155572.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616155572.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd, Walton Oaks, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd, Walton Oaks, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Loftus", 
        "givenName": "Jane", 
        "id": "sg:person.0721373417.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721373417.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, NY USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alvir", 
        "givenName": "Jose", 
        "id": "sg:person.014136347237.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014136347237.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, NY USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cicchetti", 
        "givenName": "Michael", 
        "id": "sg:person.013716416520.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013716416520.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Evidera, Bethesda, MD USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Evidera, Bethesda, MD USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lenderking", 
        "givenName": "William R.", 
        "id": "sg:person.01252606652.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252606652.22"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40120-016-0040-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037062379", 
          "https://doi.org/10.1007/s40120-016-0040-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-013-7051-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012089411", 
          "https://doi.org/10.1007/s00415-013-7051-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00415-014-7373-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015254823", 
          "https://doi.org/10.1007/s00415-014-7373-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1750-1172-8-31", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012414979", 
          "https://doi.org/10.1186/1750-1172-8-31"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrcardio.2010.67", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042620678", 
          "https://doi.org/10.1038/nrcardio.2010.67"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12265-013-9512-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037682340", 
          "https://doi.org/10.1007/s12265-013-9512-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-08-02", 
    "datePublishedReg": "2018-08-02", 
    "description": "INTRODUCTION: Transthyretin amyloidosis (ATTR amyloidosis), whether manifesting as familial amyloid polyneuropathy (ATTR-PN) or cardiomyopathy (ATTR-CM), is a progressive, debilitating, and often fatal, rare disease requiring significant caregiver support. This study aims to better characterize the burden of disease for ATTR amyloidosis patients and caregivers.\nMETHODS: Patients and caregivers in the USA and Spain were recruited through patient advocacy groups to complete a cross-sectional survey. Assessments included the 12-Item Short Form Health Survey, the Work Productivity and Activity Impairment Questionnaire, the Zarit Burden Interview, pain and symptom measures, health care resource use measures, and caregiving burden measures.\nRESULTS: Respondents included 60 ATTR amyloidosis patients and 32 caregivers. Patients registered scores up to two standard deviations below normal for physical health, impairment in quality of life, and reduced work productivity. Patients with liver transplant versus without liver transplant reported better overall outcomes, and those without liver transplant reported a greater impact on physical versus mental health. A high rate of health care utilization in the 3\u00a0months prior to the survey was reported by patients. Caregivers reported substantial burden, including poor mental health, work impairment, and much time spent providing care (mean 45.9\u00a0h/week). Work productivity was impacted for employed patients and caregivers.\nCONCLUSION: ATTR amyloidosis was associated with high levels of impairment in many domains, including physical health, quality of life, and reduced productivity. Providing care for ATTR amyloidosis patients is associated with a negative impact on the mental health of caregivers. These results highlight the substantial burden of ATTR amyloidosis for patients and caregivers.\nTRIAL REGISTRATION: ClinicalTrials.gov: NCT01604122.\nFUNDING: Pfizer.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40120-018-0106-z", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1050527", 
        "issn": [
          "2193-8253", 
          "2193-6536"
        ], 
        "name": "Neurology and Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "ATTR amyloidosis patients", 
      "liver transplant", 
      "quality of life", 
      "amyloidosis patients", 
      "mental health", 
      "substantial burden", 
      "work productivity", 
      "ATTR amyloidosis", 
      "transthyretin amyloidosis", 
      "Short Form Health Survey", 
      "physical health", 
      "Activity Impairment Questionnaire", 
      "Form Health Survey", 
      "Zarit Burden Interview", 
      "health care utilization", 
      "burden of disease", 
      "high disease burden", 
      "better overall outcomes", 
      "familial amyloid polyneuropathy", 
      "cross-sectional survey", 
      "poor mental health", 
      "patient advocacy groups", 
      "Impairment Questionnaire", 
      "Burden Interview", 
      "care utilization", 
      "work impairment", 
      "disease burden", 
      "Health Survey", 
      "rare disease", 
      "patients", 
      "amyloid polyneuropathy", 
      "caregiver support", 
      "overall outcome", 
      "resource use measures", 
      "burden measures", 
      "amyloidosis", 
      "transplant", 
      "caregivers", 
      "symptom measures", 
      "impairment", 
      "burden", 
      "high rate", 
      "health", 
      "disease", 
      "care", 
      "use measures", 
      "advocacy groups", 
      "high levels", 
      "polyneuropathy", 
      "pain", 
      "debilitating", 
      "months", 
      "outcomes", 
      "measures", 
      "scores", 
      "Pfizer", 
      "questionnaire", 
      "life", 
      "survey", 
      "group", 
      "negative impact", 
      "assessment", 
      "respondents", 
      "levels", 
      "quality", 
      "study", 
      "great impact", 
      "interviews", 
      "impact", 
      "rate", 
      "standard deviation", 
      "support", 
      "utilization", 
      "time", 
      "results", 
      "USA", 
      "Spain", 
      "deviation", 
      "domain", 
      "productivity", 
      "significant caregiver support", 
      "health care resource use measures", 
      "care resource use measures", 
      "NCT01604122"
    ], 
    "name": "Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers", 
    "pagination": "349-364", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105964805"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40120-018-0106-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30073497"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40120-018-0106-z", 
      "https://app.dimensions.ai/details/publication/pub.1105964805"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_767.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40120-018-0106-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40120-018-0106-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40120-018-0106-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40120-018-0106-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40120-018-0106-z'


 

This table displays all metadata directly associated to this object as RDF triples.

222 TRIPLES      22 PREDICATES      117 URIs      102 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40120-018-0106-z schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1117
4 schema:author Nc668ceb4af444cf783de283e54cefc22
5 schema:citation sg:pub.10.1007/s00415-013-7051-7
6 sg:pub.10.1007/s00415-014-7373-0
7 sg:pub.10.1007/s12265-013-9512-x
8 sg:pub.10.1007/s40120-016-0040-x
9 sg:pub.10.1038/nrcardio.2010.67
10 sg:pub.10.1186/1750-1172-8-31
11 schema:datePublished 2018-08-02
12 schema:datePublishedReg 2018-08-02
13 schema:description INTRODUCTION: Transthyretin amyloidosis (ATTR amyloidosis), whether manifesting as familial amyloid polyneuropathy (ATTR-PN) or cardiomyopathy (ATTR-CM), is a progressive, debilitating, and often fatal, rare disease requiring significant caregiver support. This study aims to better characterize the burden of disease for ATTR amyloidosis patients and caregivers. METHODS: Patients and caregivers in the USA and Spain were recruited through patient advocacy groups to complete a cross-sectional survey. Assessments included the 12-Item Short Form Health Survey, the Work Productivity and Activity Impairment Questionnaire, the Zarit Burden Interview, pain and symptom measures, health care resource use measures, and caregiving burden measures. RESULTS: Respondents included 60 ATTR amyloidosis patients and 32 caregivers. Patients registered scores up to two standard deviations below normal for physical health, impairment in quality of life, and reduced work productivity. Patients with liver transplant versus without liver transplant reported better overall outcomes, and those without liver transplant reported a greater impact on physical versus mental health. A high rate of health care utilization in the 3 months prior to the survey was reported by patients. Caregivers reported substantial burden, including poor mental health, work impairment, and much time spent providing care (mean 45.9 h/week). Work productivity was impacted for employed patients and caregivers. CONCLUSION: ATTR amyloidosis was associated with high levels of impairment in many domains, including physical health, quality of life, and reduced productivity. Providing care for ATTR amyloidosis patients is associated with a negative impact on the mental health of caregivers. These results highlight the substantial burden of ATTR amyloidosis for patients and caregivers. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01604122. FUNDING: Pfizer.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree true
17 schema:isPartOf N584e704b5f59461080431aa172d3f1e3
18 N630d02eb327e4b0cbd27de0c0fae4d92
19 sg:journal.1050527
20 schema:keywords ATTR amyloidosis
21 ATTR amyloidosis patients
22 Activity Impairment Questionnaire
23 Burden Interview
24 Form Health Survey
25 Health Survey
26 Impairment Questionnaire
27 NCT01604122
28 Pfizer
29 Short Form Health Survey
30 Spain
31 USA
32 Zarit Burden Interview
33 advocacy groups
34 amyloid polyneuropathy
35 amyloidosis
36 amyloidosis patients
37 assessment
38 better overall outcomes
39 burden
40 burden measures
41 burden of disease
42 care
43 care resource use measures
44 care utilization
45 caregiver support
46 caregivers
47 cross-sectional survey
48 debilitating
49 deviation
50 disease
51 disease burden
52 domain
53 familial amyloid polyneuropathy
54 great impact
55 group
56 health
57 health care resource use measures
58 health care utilization
59 high disease burden
60 high levels
61 high rate
62 impact
63 impairment
64 interviews
65 levels
66 life
67 liver transplant
68 measures
69 mental health
70 months
71 negative impact
72 outcomes
73 overall outcome
74 pain
75 patient advocacy groups
76 patients
77 physical health
78 polyneuropathy
79 poor mental health
80 productivity
81 quality
82 quality of life
83 questionnaire
84 rare disease
85 rate
86 resource use measures
87 respondents
88 results
89 scores
90 significant caregiver support
91 standard deviation
92 study
93 substantial burden
94 support
95 survey
96 symptom measures
97 time
98 transplant
99 transthyretin amyloidosis
100 use measures
101 utilization
102 work impairment
103 work productivity
104 schema:name Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers
105 schema:pagination 349-364
106 schema:productId N08caf006501c425ebd3e3373a2375789
107 N426c0a854bd240fda2ed4fce83cdb0ab
108 Nf991784aa3ae453c98bcf0d788251d08
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105964805
110 https://doi.org/10.1007/s40120-018-0106-z
111 schema:sdDatePublished 2021-11-01T18:32
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher Ne7da4205a254422697d35098659bb2c2
114 schema:url https://doi.org/10.1007/s40120-018-0106-z
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N08caf006501c425ebd3e3373a2375789 schema:name pubmed_id
119 schema:value 30073497
120 rdf:type schema:PropertyValue
121 N0f0baa358ba54c9bb935ac16de88f87d rdf:first sg:person.0721626343.01
122 rdf:rest Nb684560d1d9548328889ebca0f884d25
123 N426c0a854bd240fda2ed4fce83cdb0ab schema:name dimensions_id
124 schema:value pub.1105964805
125 rdf:type schema:PropertyValue
126 N584e704b5f59461080431aa172d3f1e3 schema:volumeNumber 7
127 rdf:type schema:PublicationVolume
128 N5f5d7fe8dbb84ea6bc3ec3d9f5f63bd3 rdf:first sg:person.013716416520.04
129 rdf:rest Nf9210a9b6fac40409df131a29fdd663b
130 N630d02eb327e4b0cbd27de0c0fae4d92 schema:issueNumber 2
131 rdf:type schema:PublicationIssue
132 N8cd8ba72e7b1425eb8d66346cc2dcddd rdf:first sg:person.0721373417.04
133 rdf:rest N925b697703e0453e9c34d109479e661b
134 N925b697703e0453e9c34d109479e661b rdf:first sg:person.014136347237.18
135 rdf:rest N5f5d7fe8dbb84ea6bc3ec3d9f5f63bd3
136 Nb684560d1d9548328889ebca0f884d25 rdf:first sg:person.0616155572.62
137 rdf:rest N8cd8ba72e7b1425eb8d66346cc2dcddd
138 Nc668ceb4af444cf783de283e54cefc22 rdf:first sg:person.010273426173.78
139 rdf:rest N0f0baa358ba54c9bb935ac16de88f87d
140 Ne7da4205a254422697d35098659bb2c2 schema:name Springer Nature - SN SciGraph project
141 rdf:type schema:Organization
142 Nf9210a9b6fac40409df131a29fdd663b rdf:first sg:person.01252606652.22
143 rdf:rest rdf:nil
144 Nf991784aa3ae453c98bcf0d788251d08 schema:name doi
145 schema:value 10.1007/s40120-018-0106-z
146 rdf:type schema:PropertyValue
147 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
148 schema:name Medical and Health Sciences
149 rdf:type schema:DefinedTerm
150 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
151 schema:name Clinical Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
154 schema:name Public Health and Health Services
155 rdf:type schema:DefinedTerm
156 sg:journal.1050527 schema:issn 2193-6536
157 2193-8253
158 schema:name Neurology and Therapy
159 schema:publisher Springer Nature
160 rdf:type schema:Periodical
161 sg:person.010273426173.78 schema:affiliation grid-institutes:grid.410513.2
162 schema:familyName Stewart
163 schema:givenName Michelle
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010273426173.78
165 rdf:type schema:Person
166 sg:person.01252606652.22 schema:affiliation grid-institutes:None
167 schema:familyName Lenderking
168 schema:givenName William R.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252606652.22
170 rdf:type schema:Person
171 sg:person.013716416520.04 schema:affiliation grid-institutes:grid.410513.2
172 schema:familyName Cicchetti
173 schema:givenName Michael
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013716416520.04
175 rdf:type schema:Person
176 sg:person.014136347237.18 schema:affiliation grid-institutes:grid.410513.2
177 schema:familyName Alvir
178 schema:givenName Jose
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014136347237.18
180 rdf:type schema:Person
181 sg:person.0616155572.62 schema:affiliation grid-institutes:None
182 schema:familyName Murphy
183 schema:givenName Brian
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616155572.62
185 rdf:type schema:Person
186 sg:person.0721373417.04 schema:affiliation grid-institutes:grid.418566.8
187 schema:familyName Loftus
188 schema:givenName Jane
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721373417.04
190 rdf:type schema:Person
191 sg:person.0721626343.01 schema:affiliation grid-institutes:None
192 schema:familyName Shaffer
193 schema:givenName Shannon
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721626343.01
195 rdf:type schema:Person
196 sg:pub.10.1007/s00415-013-7051-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012089411
197 https://doi.org/10.1007/s00415-013-7051-7
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s00415-014-7373-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015254823
200 https://doi.org/10.1007/s00415-014-7373-0
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s12265-013-9512-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037682340
203 https://doi.org/10.1007/s12265-013-9512-x
204 rdf:type schema:CreativeWork
205 sg:pub.10.1007/s40120-016-0040-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037062379
206 https://doi.org/10.1007/s40120-016-0040-x
207 rdf:type schema:CreativeWork
208 sg:pub.10.1038/nrcardio.2010.67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042620678
209 https://doi.org/10.1038/nrcardio.2010.67
210 rdf:type schema:CreativeWork
211 sg:pub.10.1186/1750-1172-8-31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012414979
212 https://doi.org/10.1186/1750-1172-8-31
213 rdf:type schema:CreativeWork
214 grid-institutes:None schema:alternateName Evidera, Bethesda, MD USA
215 schema:name Evidera, Bethesda, MD USA
216 rdf:type schema:Organization
217 grid-institutes:grid.410513.2 schema:alternateName Pfizer Inc, New York, NY USA
218 schema:name Pfizer Inc, New York, NY USA
219 rdf:type schema:Organization
220 grid-institutes:grid.418566.8 schema:alternateName Pfizer Ltd, Walton Oaks, UK
221 schema:name Pfizer Ltd, Walton Oaks, UK
222 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...